The latest price target for Novavax (NASDAQ:NVAX) was reported by HC Wainwright & Co. on February 27, 2026. The analyst firm set a price target for $16.00 expecting NVAX to rise to within 12 months (a possible 84.96% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Novavax (NASDAQ:NVAX) was provided by HC Wainwright & Co., and Novavax maintained their buy rating.

The last upgrade for Novavax Inc happened on May 10, 2024 when B of A Securities raised their price target to $12. B of A Securities previously had an underperform for Novavax Inc.

The last downgrade for Novavax Inc happened on August 20, 2025 when B of A Securities changed their price target from $9 to $7 for Novavax Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novavax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novavax was filed on February 27, 2026 so you should expect the next rating to be made available sometime around February 27, 2027.

While ratings are subjective and will change, the latest Novavax (NVAX) rating was a maintained with a price target of $11.00 to $16.00. The current price Novavax (NVAX) is trading at is $8.65, which is out of the analyst’s predicted range.